Massive M&A activity is not just a sign of a healthy market; it's the foundational cause of the current rally. Capital returned to investors from these acquisitions must be redeployed, directly fueling a record year for equity deals and providing the momentum for the IPO market's return.
With half of the $150B in recent M&A deals being private company takeouts, venture capitalists now see a clear, profitable exit path outside of the public markets. This has captured their attention and is encouraging continued early-stage investment into promising biotechs, even before the IPO market fully recovers.
The current IPO market is not a free-for-all but is instead highly selective, acting as a quality filter. This curated approach is why the recent class of IPOs has performed so strongly, with 80% trading above their issue price. This success builds investor confidence and creates a positive feedback loop for future offerings.